US FDA plans to lower recommended age for Pfizer / BioNTech COVID-19 boosters By Reuters

NEW YORK (Reuters) – A senior U.S. Food and Drug Administration official said on Friday the agency was considering lowering the recommended age for people who should receive booster shots of the Pfizer / BioNTech COVID vaccine -19 to age 40, based on data from Israel suggesting the vaccine’s efficacy is waning.

Israeli scientists presented “data that looked compelling in the 40 and over age group,” said Dr. Peter Marks, FDA director for Biologics Evaluation and Research, addressing the agency advisory committee on vaccines and related biologics.

Disclaimer: Fusion media would like to remind you that the data contained in this site is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by the exchanges but rather by market makers. Therefore, the prices may not be exact and differ from the actual market price, which means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may incur as a result of the use of such data.

Fusion media or anyone involved with Fusion Media will accept no responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.